SCHEMBL180184

SCHEMBL180184

Cc1cc(OC2CCN(C3CCN(C(=O)c4ccccc4S(C)(=O)=O)CC3)CC2)ccc1Cl

nearest known ligand 0.65

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 19/20 0.65
CCR3 P51677 19/20 0.65
KCNH2 Q12809 3/20 0.54
CHRM2 P08172 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4717850 0.93 HRH1 (0.75) HRH1CCR3KCNH2
SCHEMBL6570388 0.84 HRH1 (0.80) HRH1CCR3KCNH2
SCHEMBL5411487 0.82 HRH1 (0.90) HRH1CCR3KCNH2
SCHEMBL3087657 0.80 HRH3 (0.65) HRH1CCR3CHRM2
SCHEMBL5415414 0.80 HRH1 (0.73) HRH1CCR3KCNH2
SCHEMBL18841130 0.79 HRH1 (1.00) HRH1CCR3KCNH2
SCHEMBL5404949 0.78 HRH1 (0.80) HRH1CCR3KCNH2
SCHEMBL5655573 0.78 CCR3 (0.66) HRH1CCR3KCNH2
SCHEMBL5417144 0.76 HRH1 (1.00) HRH1CCR3KCNH2
SCHEMBL5409041 0.76 HRH1 (1.00) HRH1CCR3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130023562-A1 NOVEL PIPERIDINE DERIVATIVES ASTRAZENECA AB (SE) 2013-01-24 US disclosed
US-8314127-B2 Piperidine derivatives ASTRAZENECA AB (SE) 2012-11-20 US disclosed
EP-1912941-B1 PIPERIDINE DERIVATIVES ASTRAZENECA AB (SE) 2012-11-14 EP disclosed
EP-2402316-A1 Piperidine derivatives AstraZeneca AB (Publ) (SE) 2012-01-04 EP disclosed
US-20090197914-A1 Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them ASTRAZENECA AB (SE) 2009-08-06 US disclosed
US-20090118288-A1 N-Benzyl-Morpholine Derivatives as Modulators of the Chemokine Receptor ASTRAZENECA AB (SE) 2009-05-07 US disclosed
US-20090023733-A1 Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them ASTRAZENECA AB (SE) 2009-01-22 US disclosed
US-20090012125-A1 Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them CAGE PETER 2009-01-08 US disclosed
EP-1996551-A2 PIPERIDINE DERIVATIVES, THEIR PROCESS FOR PREPARATION, THEIR USE AS THERAPEUTIC AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. AstraZeneca AB (SE) 2008-12-03 EP disclosed
EP-1994003-A1 PIPERIDINE DERIVATIVES, THEIR PROCESS FOR PREPARATION, THEIR USE AS THERAPEUTIC AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM . AstraZeneca AB (SE) 2008-11-26 EP disclosed
US-20080275084-A1 Piperidines for the Treatment of Chemokine Mediated Diseases ASTRAZENECA AB (SE) 2008-11-06 US disclosed
US-20080207688-A1 Novel Piperidine Derivatives ASTRAZENECA AB (SE) 2008-08-28 US disclosed
EP-1919884-A1 N-BENZYL-MORPHOLINE DERIVATIVES AS MODULATORS OF THE CHEMOKINE RECEPTOR AstraZeneca AB (SE) 2008-05-14 EP disclosed
EP-1888526-A1 PIPERIDINES FOR THE TREATMENT OF CHEMOKINE MEDIATED DISEASES AstraZeneca AB (SE) 2008-02-20 EP disclosed
WO-2007102769-A2 PIPERIDINE DERIVATIVES, THEIR PROCESS FOR PREPARATION, THEIR USE AS THERAPEUTIC AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ASTRAZENECA AB (SE) 2007-09-13 WO disclosed
WO-2007102768-A1 PIPERIDINE DERIVATIVES, THEIR PROCESS FOR PREPARATION, THEIR USE AS THERAPEUTIC AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM . ASTRAZENECA AB (SE) 2007-09-13 WO disclosed
WO-2007011292-A1 N-BENZYL-MORPHOLINE DERIVATIVES AS MODULATORS OF THE CHEMOKINE RECEPTOR ASTRAZENECA AB (SE) 2007-01-25 WO disclosed
WO-2006126947-A1 PIPERIDINES FOR THE TREATMENT OF CHEMOKINE MEDIATED DISEASES ASTRAZENECA AB (SE) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207688-A1 Novel Piperidine Derivatives CCR3, CCR1, CCR4 HRH1 276/4885CCR3 1/4885KCNH2 4090/4885
US-20090197914-A1 Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them CCR3, CCR1, CCR4 HRH1 379/4885CCR3 1/4885KCNH2 3793/4885
US-20090012125-A1 Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them CCR3, CCR1, CCR5 HRH1 420/4885CCR3 1/4885KCNH2 3712/4885
US-20090023733-A1 Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them CCR3, CCR1, CCR5 HRH1 420/4885CCR3 1/4885KCNH2 3712/4885
US-20080275084-A1 Piperidines for the Treatment of Chemokine Mediated Diseases CCR3, CCR1, CCR4 HRH1 38/4885CCR3 1/4885KCNH2 2199/4885
US-20090118288-A1 N-Benzyl-Morpholine Derivatives as Modulators of the Chemokine Receptor CCR3, CCR1, CCR5 HRH1 290/4885CCR3 1/4885KCNH2 4469/4885
US-20130023562-A1 NOVEL PIPERIDINE DERIVATIVES CCR3, CCR1, CCR4 HRH1 276/4885CCR3 1/4885KCNH2 4090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.